ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
‘Unprecedented’ results in AZ’ late-stage Lynparza trial
June 05, 2019New data from a Phase III trial of AstraZeneca and MSD’s Lynparza (olaparib) has shown that 22% of patients receiving the monotherapy remained free of disease progression after two years vs. 10% on placebo, making the drug the first PARP inhibitor to demo -
‘Unprecedented’ results in AZ’ late-stage Lynparza trial
June 03, 2019Pancreatic cancer is the 12th most common cancer worldwide, with 458,918 new cases in 2018 alone.
Pharma Sources Insight January 2025
